Forteo ® (teriparatide [rDNA origin] injection)

20-mcg daily dose in a 2.4-mL prefilled delivery device

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

FORTEO® (teriparatide [rDNA origin] injection): Bone Mineral Density Response

Forteo significantly increased lumbar spine, femoral neck, and total hip BMD from baseline in PMW and men with osteoporosis and in patients with GIO.

Detailed Information

Effects of Teriparatide on BMD in Postmenopausal Women With Osteoporosis

Results from a LOCF analysis showed that teriparatide significantly increased baseline to endpoint BMD at the LS, FN, and TH in postmenopausal women with osteoporosis.1

Table 1. Mean Percentage Change in BMD From Baseline to Endpointa in Postmenopausal Women With Osteoporosis Treated With Teriparatide for a Median of 19 Months 1

 

Teriparatide

n=541

Placebo

n=544

LS BMD

9.7%b

1.1%

FN BMD

2.8%c

-0.7%

TH BMD

2.6%c

-1.0%

Abbreviations: BMD = bone mineral density; FN = femoral neck; LS = lumbar spine; TH = total hip.

a Intent-to-treat analysis, last observation carried forward.

b p<.001 compared with placebo.

c p<.05 compared with placebo.

In a subset of women for whom data were available at every time point (3, 6, 12, and 18 months; n=129), teriparatide significantly increased LS BMD by 3.9% at 3 months of treatment and 11.8% at 18 months.2

Effects of Teriparatide on BMD in Men With Primary or Hypogonadal Osteoporosis

Using a LOCF analysis, results showed that teriparatide treatment, for a median of 10 months, significantly increased baseline LS BMD by 5.9% compared to placebo (p<.001). Significant increases in LS BMD were seen at 3 months.1

Teriparatide treatment significantly increased FN BMD by 1.5% from baseline compared to the placebo group (p<.05).1

There was no significant difference observed in the change from baseline to endpoint TH BMD.1

Effects of Teriparatide on BMD in Men and Women With Glucocorticoid-Induced Osteoporosis

Results from a LOCF analysis showed that teriparatide significantly increased baseline to endpoint BMD at the LS, FN, and TH by 7.2%, 3.7%, and 3.6%, respectively, at the 18-month endpoint (p<.001 at all sites).1

Enclosed Prescribing Information

FORTEO® (teriparatide [rDNA origin] injection), Lilly

Reference

1. Forteo [package insert]. Indianapolis IN: Eli Lilly and Company; 2019.

2. Data on file, Eli Lilly and Company and/or one of its subsidiaries.

Glossary

BMD = bone mineral density

FN = femoral neck

LS = lumbar spine

LOCF = last observation carried forward

TH = total hip

Date of Last Review: January 28, 2020

Contact Lilly

Call Us

If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.

Available Mon - Fri, 8am - 7pm ET

Or you can

Ask us a question Chat with us

Submit a Request

Visit Us @LillyMedical